> All clinical trials suffer from risks of bias in their design and conduct, as assessed by the Cochrane Risk of Bias 2.0 tool that assesses trial biases with the grades of “some concern, low, moderate, high, or serious”. Although one group of authors has assessed many of the trials as having moderate to severe risks of bias, performing meta-analyses of these trials can more accurately detect the true effects despite individual trial biases. Multiple groups, including ours, have performed meta-analyses of these trials, with all groups finding consistent benefits amongst the trials. In fact, the consistency of trial results from both sets of randomized and observational controlled trials from varied centers and countries and trial sizes and disease phases lend even more validity to the estimates of benefit.
[1) https://covid19criticalcare.com/ivermectin-in-covid-19/faq-o...